Edina, Minn. – September 18, 2026 -- ReEmerge, Inc. has closed an oversubscribed $37 million Series A financing and exited stealth mode to advance a novel therapy targeting chronic cognitive impairment caused by traumatic brain injury (TBI).

Dallas – September 18, 2026 -- Nanoscope Therapeutics will unveil four-year follow-up data showing sustained visual acuity gains from its gene therapy MOGENRY® in retinitis pigmentosa patients, with the FDA already having accepted and filed the company's Biologics License Application.

Boston – September 17, 2026 -- Xylo Bio has dosed the first participants in a Phase 1 clinical trial of XYL-1001, a selective 5-HT2A receptor agonist targeting major depressive disorder (MDD), marking the company's transition to a clinical-stage biotechnology organization.

Stockholm – September 17, 2026 -- SciBase Holding AB has pushed back the first day of trading in subscription rights and paid subscribed shares (BTA) tied to its ongoing rights issue by one day, moving the start date from September 15, 2026 to September 16, 2026 on Nasdaq First North Growth Market.

The subscription period itself remains unchanged, running from September 15 through September 29, 2026.

Evanston, Illinois – September 17, 2026 -- ZS has been named a Leader in the IDC MarketScape: Worldwide Life Science R&D RWD/Real-World Evidence for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment (IDC #US54122226, August 2026).

The recognition marks ZS's second IDC MarketScape Leader designation in 2026, following its May 2026 placement as a Leader in the Worldwide Life Sciences R&D Strategic Consulting Services assessment (IDC #US53009826).

Raleigh – September 17, 2026 -- Endpoint Clinical L.P., a portfolio company of Arsenal Capital Partners, has acquired Boston-based Bluefin, a clinical supply forecasting and planning technology provider, expanding Endpoint's footprint from randomization and trial supply management (RTSM) into upstream supply chain planning.

Jersey City, N.J. – September 17, 2026 -- Tenon Medical, Inc. (NASDAQ: TNON) has closed a warrant inducement agreement generating $2,872,338.58 in gross proceeds from an institutional investor exercising 572,179 outstanding warrants in full.

Institutional investor exercises warrants for immediate cash proceeds

The exercising holder converted 572,179 existing warrants into common stock, delivering gross cash proceeds of $2,872,338.58 to Tenon before deducting advisor fees and other expenses.

Short Hills, N.J. – September 17, 2026 -- Doceree has launched Intent Powered HCP Suite, extending its real-time clinical signal technology into Connected TV, LinkedIn and programmatic advertising, three channels the company says still rely on claims data that lags weeks behind actual prescribing decisions.

San Francisco – September 17, 2026 -- Deloitte has expanded its alliance with Salesforce to launch FastForward for Life Sciences, a preconfigured CRM accelerator that cuts implementation timelines to four to six months, twice as fast as traditional customized transformations.

NEW YORK – September 17, 2026 -- Inductive Bio has launched Indy, an AI medicinal chemistry agent that scored 89% accuracy on 84 real-program dose-response curves, versus 48% for Claude Opus 5 and 39% for GPT-5.6 Sol run at maximum effort settings.